Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol

Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2003, Pages 2534-2541

  Ikuina, Yoji ^a   Amishiro, Nobuyoshi ^a   Miyata, Mayumi ^a   Narumi, Hiroaki ^a   Ogawa, Harumi ^a   Akiyama, Tadakazu ^a   Shiotsu, Yukimasa ^a   Akinaga, Shiro ^a   Murakata, Chikara ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HERBIMYCIN; KF25706; KF29158; O CARBAMOYLMETHYLOXIME DERIVATIVE; PROTEIN; PROTEIN RAF 1 KINAE; PROTEIN TYROSINE KINASE; PROTEIN V SRC TYROSINE KINASE; RADICICOL; RADICICOL 6 [O (PIPERIDINOCARBONYL)METHYLOXIME]; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL LINE; CELL TRANSFORMATION; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; NONHUMAN; NUDE MOUSE; ONCOGENE K RAS; VISUAL DISORDER; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTONES; MACROLIDES; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEIN PP60(V-SRC); OXIMES; PHOSPHORYLATION; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-RAF; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037763045     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030110r     Document Type: Article

References (33)

1. Delmotte, P.; Delmotte-Plaquee, J. A New Antifungal Substance of Fungal Origin. Nature 1953, 171, 344.
2. v-src Protein Kinase Both in Vivo and in Vitro by Radicicol. Cancer Res. 1992, 52, 6926-6930.
3. Kwon, H. J.; Yoshida, M.; Abe, K.; Horinouchi, S.; Beppu, T. Radicicol, an Agent Inducing the Reversal of Transformed Phenotypes of src-Transformed Fibroblasts. Biosci., Biotechnol., Biochem. 1992, 56, 538-539.
4. Zhao, J. F.; Nakano, H.; Sharma, S. Suppression of RAS and MOS Transformation by Radicicol. Oncogene 1995, 11, 161-173.
5. Kwon, H. J.; Yoshida, M.; Nagaoka, R.; Obinata, T.; Beppu, T.; Horinouchi, S. Suppression of Morphological Transformation by Radicicol Is Accompanied by Enhanced Gelsolin Expression. Oncogene 1997, 15, 2625-2631.
6. Soga, S.; Kozawa, T.; Narumi, H.; Akinaga, S.; Irie, K.; Matsumoto, K.; Sharma, S. V.; Nakano, H.; Mizukami, T.; Hara, M. Radicicol Leads to Selective Depletion of Raf Kinase and Disrupts K-Ras-Activated Aberrant Signaling Pathway. J. Biol. Chem. 1998, 273, 822-828.
7. Soga, S.; Neckers, L. M.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga, S. KF25706, a Novel Oxime Derivative of Radicicol, Exhibits in Vivo Antitumor Activity via Selective Depletion of Hsp90 Binding Signaling Molecules. Cancer Res. 1999, 59, 2931-2938.
8. Agatsuma, T.; Ogawa, H.; Akasaka, K.; Asai, A.; Yamashita, Y.; Mizukami, T.; Akinaga, S.; Saitoh, Y. Halohydrin and Oxime Derivatives of Radicicol: Synthesis and Antitumor Activities. Bioorg. Med. Chem. 2002, 10, 3445-3454.
9. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L. M. Antibiotic Radicicol Binds to the N-Terminal Domain of Hsp90 and Shares Important Biologic Activities with Geldanamycin. Cell Stress Chaperones 1998, 3, 100-108.
10. Sharma, S. V.; Agatsuma, T.; Nakano, H. Targeting of the Protein Chaperone, HSP90, by the Transformation Suppressing Agent, Radicicol. Oncogene 1998, 16, 2639-2645.
11. Schulte, T. W.; Akinaga, S.; Murakata, C.; Agatsuma, T.; Sugimoto, S.; Nakano, H.; Lee, Y. S.; Simen, B. B.; Argon, Y.; Felts, S.; Toft, D. O.; Neckers, L. M.; Sharma, S. V. Interaction of Radicicol with Members of the Heat Shock Protein 90 Family of Molecular Chaperones. Mol. Endocrinol. 1999, 13, 1435-1448.
12. v-src Kinase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 7074-7078.
13. Hartson, S. D.; Matts, R. L. Association of Hsp90 with Cellular Src-Family Kinases in a Cell-Free System Correlates with Altered Kinase Structure and Function. Biochemistry 1994, 33, 8912-8920.
14. v-src Heteroprotein Complex Formation by Benzoquinone Ansamycins: Essential Role for Stress Proteins in Oncogenic Transformation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8324-8328.
15. Stancato, L. F.; Chow, Y. H.; Hutchison, K. A.; Perdew, G. H.; Jove, R.; Pratt, W. B. Raf Exists in a Native Heterocomplex with Hsp90 and p50 That Can Be Reconstituted in a Cell-Free System. J. Biol. Chem. 1993, 268, 21711-21716.
16. Schulte, T. W.; Blagosklonny, M. V.; Ingui, C.; Neckers, L. Disruption of the Raf-1-Hsp90 Molecular Complex Results in Destabilization of Raf-1 and Loss of Raf-1-Ras Association. J. Biol. Chem. 1995, 270, 24585-24588.
17. Schulte, T. W.; Blagosklonny, M. V.; Romanova, L.; Mushinski, J. F.; Monia, B. P.; Johnston, J. F.; Nguyen, P.; Trepel, J.; Neckers, L. M. Destabilization of Raf-1 by Geldanamycin Leads to Disruption of the Raf-1-MEK-Mitogen-Activated Protein Kinase Signalling Pathway. Mol. Cell. Biol. 1996, 16, 5839-5845.
18. Stancato, L. F.; Silverstein, A. M.; Owens-Grillo, J. K.; Chow, Y. H.; Jove, R.; Pratt, W. B. The Hsp90-Binding Antibiotic Geldanamycin Decreases Raf Levels and Epidermal Growth Factor Signaling without Disrupting Formation of Signaling Complexes or Reducing the Specific Enzymatic Activity of Raf Kinase. J. Biol. Chem. 1997, 272, 4013-4020.
19. erbB2. J. Biol. Chem. 1996, 271, 4974-4977.
20. Cdc37 is a Protein Kinase-Targeting Subunit of Hsp90 That Binds and Stabilizes Cdk4. Genes Dev. 1996, 10, 1491-1502.
21. Pratt, W. B.; Toft, D. O. Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones. Endocr. Rev. 1997, 18, 306-360.
22. Blagosklonny, M. V.; Toretsky, J.; Neckers, L. Geldanamycin Selectively Destabilizes and Conformationally Alters Mutated p53. Oncogene 1995, 11, 933-939.
23. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity. Invest. New Drugs 1999, 17, 361-373.
24. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal Structure of an Hsp90-Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent. Cell 1997, 89, 239-250.
25. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42, 260-266.
26. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A Small Molecule Designed To Bind to the Adenine Nucleotide Pocket of Hsp90 Causes Her2 Degradation and the Growth Arrest and Differentiation of Breast Cancer Cells. Chem. Biol. 2001, 8, 289-299.
27. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a Purine-Scaffold Novel Class of Hsp90 Binders That Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
28. erbB-2 in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives. J. Med. Chem. 1995, 38, 3806-3812.
29. Agnew, E. B.; Wilson, R. H.; Grem, J. L.; Neckers, L.; Bi, D.; Takimoto, C. H. Measurement of the Novel Antitumor Agent 17(Allylamino)-17-demethoxygeldanamycin in Human Plasma by High-Performance Liquid Chromatography. J. Chromatogr. B 2001, 755, 237-243.
30. Watanabe, Y.; Morimoto, S.; Adachi, T.; Kashimura, M.; Asaka, T. Chemical Modification of Erythromycins. IX. Selective Methylation at the C-6 Hydroxyl Group of Erythromycin A Oxime Derivatives and Preparation of Clarithromycin. J. Antibiot. 1993, 46, 647-660.
31. 1 Phase Accumulation against Chronic Myelogenous Leukemia Cells through Destabilization of Bcr-Abl with Hsp90 Complex. Blood 2000, 96, 2284-2291.
32. Soga, S.; Sharma, S. V.; Shiotsu, Y.; Shimizu, M.; Tahara, H.; Yamaguchi, K.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Kurebayashi, J.; Schulte, T. W.; Neckers, L. M.; Akinaga, S. Stereospecific Antitumor Activity of Radicicol Oxime Derivatives. Cancer Chemother. Pharmacol. 2001, 48, 435-445.
33. Geran, R. I.; Greenberg, N. H.; MacDonald, M. M.; Schumacher, A. M.; Abbott, B. J. Protocols for Screening Chemical Agents and Natural Products against Animal Tumors and Other Biological Systems. Cancer Chemother. Rep., Part 3 1972, 3, 1-103.